David Novack, President & COO of Dynavax Technologies Corp (NASDAQ:DVAX), sold 9,000 shares of the company on January 2, 2024, according to a recent SEC filing. The transaction was executed at an average price of $14.45 per share, resulting in a total value of $130,050.
Dynavax Technologies Corp is a biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's first commercial product, HEPLISAV-B, is approved in the United States for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older.
Over the past year, David Novack has sold a total of 186,515 shares of Dynavax Technologies Corp and has not made any purchases of the stock. This latest transaction continues a pattern of insider selling activity at the company.
The insider transaction history for Dynavax Technologies Corp shows a trend of insider sales, with 18 insider sells and no insider buys over the past year.
On the valuation front, Dynavax Technologies Corp's shares were trading at $14.45 on the day of the insider's recent sale, giving the stock a market cap of $1.937 billion. The price-earnings ratio stands at 38.41, which is above both the industry median of 24.355 and the company's historical median price-earnings ratio.
The stock's price-to-GF-Value ratio is 2.03, with a current share price of $14.45 and a GF Value of $7.13, indicating that Dynavax Technologies Corp is significantly overvalued based on its GF Value.
The GF Value is calculated considering historical trading multiples, a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
